GYRE THERAPEUTICS, INC. Cash Flow Statement
GYRE / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
GYRE THERAPEUTICS, INC. generated $1M in operating cash flow and negative free cash flow of $180,000 in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $9.9M | $17.9M | $4.3M | $4.3M | -$87.9M | -$55.2M | -$55.2M | -$30.1M | -$21.6M | -$16.9M | -$14.8M | -$6.6M | -$10.0M | -$7.0M | -$39.4M |
| Depreciation & Amortization | $2.5M | $1.5M | $1.1M | $1.1M | $290.0K | $146.0K | $146.0K | $149.0K | $173.0K | $389.0K | $470.0K | $680.0K | $974.0K | $2.2M | $1.8M |
| Operating Cash Flow | $1.0M | -$3.6M | $10.7M | $10.7M | -$83.8M | -$43.6M | -$43.6M | -$28.6M | -$19.9M | -$18.5M | -$19.1M | -$6.4M | -$40.6M | -$64.2M | -$24.3M |
| Capital Expenditures | $1.2M | $2.3M | $5.0M | $5.0M | $839.0K | - | $64.0K | $376.0K | $23.0K | $468.0K | $272.0K | $4.0K | $41.0K | $333.0K | $200.0K |
| Free Cash Flow | -$180.0K | -$6.0M | $5.7M | $5.7M | -$84.6M | - | -$43.7M | -$28.9M | -$20.0M | -$18.9M | -$19.4M | -$6.4M | -$40.7M | -$64.6M | -$24.5M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | $82.0K | - | - | - | - |
| Dividends Paid | - | - | - | $45.0M | - | - | - | - | - | - | - | - | - | - | - |
| FCF Margin | -0.1% | -5.6% | 5.6% | 5.6% | -1152.8% | - | - | -482150.0% | - | - | - | -7348.3% | -1120.2% | -111.6% | -97.6% |